Physician profile
Lawrence J Zelonis
NPI 1427147503
$1,460.17
in general payments reported to CMS, 2019-2025
10 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.73 · 2022: $152 · 2023: $281 · 2024: $480 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.32 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $292.34 | 2022-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $243.86 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $219.42 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $202.08 | 2023-2025 | Auvelity |
| Alkermes, INC. | $190.30 | 2024-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.40 | 2022-2025 | Caplyta |
| Lundbeck LLC | $67.32 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $63.45 | 2024-2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $27.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.79 | 2024 | Jardiance, Tradjenta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Zelonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.